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Azole-Resistant  
Aspergillus  
fumigatus, Iran
To the Editor: Aspergillus fu-
migatus causes a variety of diseases 
in humans. The drugs recommended 
for treatment of Aspergillus diseases 
are the mold-active azole antifungal 
drugs (1). However, a wide range of 
mutations in A. fumigatus confer azole 
resistance, which commonly involves 
modifications in the cyp51A gene (2), 
the target for azole antifungal drugs.
Azole resistance is thought to be 
selected for as a result of patient ther-
apy or exposure to azole compounds 
in the environment; resistance in 
clinical A. fumigatus isolates has been 
increasingly reported in several Euro-
pean countries, Asia, and the United 
States (3–7). The most frequently 
reported resistance mechanism is a 
34-bp tandem repeat (TR
34
) in com-
bination with a substitution at codon 
98 (TR
34
/L98H) (4); this mechanism 
is believed to have been selected for 
through environmental exposure to 
azole fungicides.
Because routine in vitro suscep-
tibility testing of clinical Aspergil-
lus isolates is not common in many 
centers worldwide, the prevalence of 
azole resistance might be underesti-
mated. We investigated the prevalence 
of azole resistance in clinical A. fumig-
atus isolates stored for 6 years (2003–
2009) at Tehran University Mycology 
Reference Centre and Islamic Azad 
University, Ardabil Branch, Iran.
We investigated 124 clinical A. 
fumigatus isolates obtained from pa-
tients with Aspergillus diseases (on-
line Technical Appendix Table 1, 
wwwnc.cdc.gov/EID/article/19/5/13-
0075-Techapp1.pdf). We conducted 
strain identification, in vitro antifungal 
susceptibility testing, and sequence-
based analysis of the Cyp51A gene, 
as described (4). We performed mi-
crosatellite genotyping of all A. fu-
migatus isolates for which the MIC of 
itraconazole was >16 mg/L (8) by us-
ing a short tandem repeat A. fumigatus 
assay, and we compared the results 
with those reported for the Nether-
lands (20 isolates) and other European 
countries (24 isolates) (online Techni-
cal Appendix Figure).
The distribution of azole-resistant 
and wild-type A. fumigatus isolates 
examined in this study, according to 
year of isolation, is shown in online 
Technical Appendix Table 1. Of 124 
A. fumigatus isolates, 4 grew on the 
wells containing itraconazole and 
voriconazole, indicating a multidrug-
resistant phenotype. Of these resistant 
isolates, 3 were from patients with 
chronic pulmonary aspergillosis and 1 
was from a patient with allergic bron-
chopulmonary aspergillosis (Table).
Sequence analysis of the CYP51A 
gene indicated the presence of TR
34
/
L98H in 3 isolates and no mutations 
in the other isolate (Table). The first 
TR
34
/L98H isolate had been recov-
ered in 2005, which is relatively early 
compared with reported isolations in 
other countries (online Technical Ap-
pendix Table 2). Microsatellite typing 
of 6 short tandem repeat loci demon-
strated identical patterns for 2 of the 3 
azole-resistant isolates from Iran, but 
the TR
34
/L98H isolates from Iran did 
not cluster with those from the Neth-
erlands and other European countries, 
indicating no close genetic relatedness 
(online Technical Appendix Figure).
The TR
34
/L98H azole resistance 
mechanism was first described in 1998 
in the Netherlands; since then, its pres-
ence in clinical and environmental A. 
fumigatus isolates in multiple Euro-
pean countries and recently in Asia 
has been increasingly reported (online 
Technical Appendix Table 2) (3–7). In 
the study reported here, prevalence of 
azole resistance in clinical A. fumigatus 
isolates obtained from patients in Iran 
was 3.2%; most isolates exhibited the 
TR
34
/L98H resistance mechanism. The 
fact that the first TR
34
/L98H isolate was 
found relatively early, in 2005, under-
scores the possibility that prevalence 
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of azole resistance might be underes-
timated in many countries because in 
vitro susceptibility testing of A. fumig-
atus is not routinely performed.
Microsatellite genotypic analy-
sis of A. fumigatus isolates from the 
Netherlands and various European 
countries showed that the genetic di-
versity of TR
34
/L98H isolates is lower 
than that of wild-type controls (8). It 
has been suggested that TR
34
/L98H 
isolates might have a common ances-
tor that developed locally and subse-
quently migrated across Europe. In 
contrast, genotyping of TR
34
/L98H 
originating from India suggested a 
different dynamic; all environmental 
and clinical TR
34
/L98H isolates from 
India shared the same multilocus mi-
crosatellite genotype not found in any 
other analyzed samples, from within 
India or from the Netherlands, France, 
Germany, or the People’s Republic of 
China (9). The molecular epidemiolo-
gy of the TR
34
/L98H isolates from Iran 
suggests that they cluster apart from 
the European isolates, indicating that 
migration from Europe to Iran, or vice 
versa, is unlikely. Genotyping of more 
TR
34
/L98H isolates from the Middle 
East and comparison with those from 
India would enhance understanding 
of the origin and geographic spread of 
TR
34
/L98H.
Our study indicates that TR
34
/
L98H was in Iran in 2005; this find-
ing adds to the growing list of regions 
where acquired resistance in A. fumig-
atus of environmental origin is docu-
mented. From a global perspective, 
fungicide use is second highest in the 
Asia–Pacific regions (24%), preceded 
only by western Europe (37%) (10). 
For a bettering understand of the scale 
of this emerging public health prob-
lem and for insight into the dynam-
ics of geographic migration, surveys 
of fungal culture collections for TR
34
/
L98H and molecular typing studies 
are warranted. These data would be 
useful not only for clinical manage-
ment of Aspergillus diseases but also 
for enabling policy makers to develop 
strategies that prevent resistance se-
lection by the environmental route.
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Table. Characteristics of 4 azole-resistant clinical Aspergillus fumigatus isolates, Iran* 
Isolate 
Underlying 
disease 
Previous 
azole 
exposure 
34-bp 
tandem 
repeat† 
Amino acid 
substitution in 
cyp51A gene‡ 
 
MIC, mg/L 
Amphotericin B Itraconazole Voriconazole Posaconazole 
T-IR-AF 12 CPA Yes Positive L98H 0.5 16 4.0 0.5 
T-IR-AF 17 CPA No Positive L98H 0.5 16 4.0 0.5 
T-IR-AF 433 CPA Yes Negative ND 0.5 16 8.0 0.5 
T-IR-AF 890 ABPA No Positive L98H 0.5 16 8.0 0.25 
*CPA, chronic pulmonary aspergillosis; ND, not detected; ABPA, allergic bronchopulmonary aspergillosis. 
†34-bp tandem repeat in the promoter region of CYP51A gene. 
‡The numbers indicate the position at which an amino acid change occurs. Nucleotides are numbered from the translation start codon ATG of cyp51A. 
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Search for  
Possible Additional 
Reservoirs for  
Human Q Fever,  
the Netherlands
To the Editor: Q fever is a zoo-
nosis caused by the bacterium Coxi-
ella burnetii. The Q fever outbreak 
in the Netherlands affected ≈4,000 
humans during 2007–2010 (1). In this 
outbreak, 1 genotype of C. burnetii 
appeared to be responsible for abor-
tions in small ruminants and for clinical 
disease in humans (2,3). However, lit-
tle is known about the outbreak geno-
type and the prevalence of C. burnetii 
in possible additional reservoirs for 
human Q fever (i.e., cats, dogs, horses, 
sheep, and cattle) in the Netherlands.
We aimed to search for possible 
additional reservoirs for human Q fe-
ver in the Netherlands. Placentas from 
15 cats, 54 dogs, and 31 horses were 
collected in 2011 at 5 veterinary prac-
tices. Placentas were collected by tar-
geted sampling at breeding facilities 
and during parturition with veterinary 
assistance. In addition, 27 ovine, 11 
caprine, 16 porcine, 8 equine, and 139 
bovine placentas (originating from 
aborting animals from throughout the 
Netherlands that were submitted in 
2011 to investigate the abortion cause) 
were included in the study. Samples 
were stored at –20°C before testing.
DNA was extracted from the al-
lantochorion of the placenta and ana-
lyzed as described (2). Samples with 
sufficient DNA load (cycle threshold 
[C
t
] value <32) were typed by using 
2 multilocus variable-number tandem-
repeat analyses (MLVA) genotyping 
methods (MLVA-12 and MLVA-6), 
and the multispacer sequence typing 
method (3–5). Two C. burnetii strains 
from the Netherlands representing 
the outbreak genotype (X09003262, 
3345937) and the Nine Mile RSA 493 
were included as reference. For preva-
lence calculations, the Netherlands 
was divided in a southern part, com-
prising the Q fever hot spot area of no-
tified cases in humans and small rumi-
nants during the 2007–2010 epidemic 
(1,6), and a northern part, comprising 
the rest of the country.
C. burnetii DNA was not detected 
in placentas from cats, goats, or pigs. 
C. burnetii DNA was detected in 4 (7% 
[95% CI 0.4–14.4]) of 54 canine pla-
centas; 3 from the north and 1 from the 
south of the Netherlands. C. burnetii 
DNA was detected in 3 (8% [95% CI 
0.0–16.1]) of 39 equine placentas, all 
from the north of the country, without 
known abortion history. C. burnetii 
DNA was detected in 7 (26% [95% CI 
9.4–42.5]) of 27 ovine and in 33 (24% 
[95% CI 16.7–30.8]) of 139 bovine 
placentas. The prevalence of C. bur-
netii DNA–positive ovine and bovine 
placentas from the north and the south 
did not differ significantly.
The C. burnetii DNA load in the 
placentas from dogs (C
t
 value 37.4–
38.0) and horses (C
t 
value 35.4–37.4) 
was too low to be suitable for genotyp-
ing. Typing of 1 positive sheep sample 
resulted in an incomplete genotype, 
which is related to the outbreak geno-
type (sheep 192, Figure). Seven of the 
33 C. burnetii DNA–positive bovine 
placentas were suitable for typing. 
One sample had a genotype similar to 
the outbreak genotype (2,3). Six other 
samples revealed a (partial) genotype 
related to bovine genotypes from the 
Netherlands (2,5,7), including a novel 
one. MLVA-6 and multispacer se-
quence typing results were consistent 
with the MLVA-12 results (Figure).
Results give no indication for ma-
jor reservoirs of C. burnetii in cats, 
goats, and pigs in the Netherlands in 
2011. However, the low numbers of 
placentas may have biased the results. 
Dogs and horses should be considered 
as reservoirs for C. burnetii. The de-
tection of C. burnetii DNA–positive 
placentas in dogs and horses in the 
northern part of the country indicates 
the presence of a true reservoir rather 
than a spillover effect from the con-
taminated environment in the south. 
This observation is consistent with 
a reported seroprevalence of 13% in 
dogs in the Netherlands in 1992 (1). 
Until now, horses had been discussed 
as a risk factor in the Q fever outbreak 
in the Netherlands (8).
Prevalence data from sheep and 
cattle suggest that C. burnetii is pres-
ent in placentas in 25% of the abortion 
cases in these species. Presence of the 
outbreak genotype of C. burnetii in 
sheep has been observed (2,5), indi-
cating sheep are a reservoir for Q fe-
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